Aurobindo Pharma announced the mutual agreement with Sandoz Inc to terminate the agreement to buy the Sandoz US generic oral solids and dermatology businesses from Sandoz Inc. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within anticipated timelines.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
